DE602005017285D1 - - Google Patents
Info
- Publication number
- DE602005017285D1 DE602005017285D1 DE602005017285T DE602005017285T DE602005017285D1 DE 602005017285 D1 DE602005017285 D1 DE 602005017285D1 DE 602005017285 T DE602005017285 T DE 602005017285T DE 602005017285 T DE602005017285 T DE 602005017285T DE 602005017285 D1 DE602005017285 D1 DE 602005017285D1
- Authority
- DE
- Germany
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60537904P | 2004-08-27 | 2004-08-27 | |
| PCT/US2005/030439 WO2006026447A2 (en) | 2004-08-27 | 2005-08-26 | PRODUCTION OF TNFR-Ig FUSION PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005017285D1 true DE602005017285D1 (enExample) | 2009-12-03 |
Family
ID=35500648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005020076T Expired - Lifetime DE602005020076D1 (de) | 2004-08-27 | 2005-08-26 | Herstellung von TNFR-Fc |
| DE602005017285T Expired - Lifetime DE602005017285D1 (enExample) | 2004-08-27 | 2005-08-26 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005020076T Expired - Lifetime DE602005020076D1 (de) | 2004-08-27 | 2005-08-26 | Herstellung von TNFR-Fc |
Country Status (37)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| AU2006259664A1 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| WO2008008360A1 (en) * | 2006-07-13 | 2008-01-17 | Wyeth | Production of glycoproteins |
| JP5401319B2 (ja) * | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
| PT2078071E (pt) * | 2006-11-08 | 2015-07-16 | Wyeth Llc | Meios concebidos racionalmente para cultura de células |
| KR20090127326A (ko) * | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| CN105567627B (zh) | 2007-04-26 | 2020-09-29 | 中外制药株式会社 | 使用含高浓度氨基酸的培养基的细胞培养方法 |
| HUE027035T2 (hu) * | 2008-04-17 | 2016-08-29 | Wyeth Llc | Eljárások csont morfogenetikus fehérjék termelésének fokozására |
| CA2721585A1 (en) * | 2008-04-18 | 2009-10-22 | Shanghai Cp Guojian Pharmaceutical Co. Ltd | A concentrated medium and its usage |
| EP2331700A2 (en) | 2008-08-08 | 2011-06-15 | Biogen Idec MA Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
| MY186219A (en) | 2009-08-11 | 2021-06-30 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
| JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ， インコーポレイテッド | Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法 |
| PT3330370T (pt) | 2010-04-26 | 2021-05-11 | Novartis Ag | Processo para cultivo de células cho |
| JP6113653B2 (ja) | 2010-04-26 | 2017-04-12 | ノバルティス アーゲー | 改良型細胞培養培地 |
| WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| WO2012068134A1 (en) | 2010-11-15 | 2012-05-24 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
| WO2012147053A1 (en) | 2011-04-29 | 2012-11-01 | Biocon Research Limited | A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof |
| WO2012170938A1 (en) | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
| US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
| JP6220788B2 (ja) | 2011-10-18 | 2017-10-25 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 塩化ナトリウムによって安定化されたエタネルセプト製剤 |
| RU2663794C2 (ru) | 2011-10-21 | 2018-08-09 | Пфайзер Инк. | Добавление железа для улучшения культивирования клеток |
| NZ629309A (en) * | 2012-02-22 | 2016-03-31 | Nvip Pty Ltd | Tumour necrosis factor receptor fusion proteins and methods of using the same |
| SG11201500138VA (en) | 2012-07-09 | 2015-03-30 | Coherus Biosciences Inc | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| SI2895188T1 (en) | 2012-09-11 | 2018-05-31 | Coherus Biosciences, Inc. | CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| EP2978498B1 (en) | 2013-03-26 | 2019-07-03 | Coherus Biosciences, Inc. | Protein production method |
| KR101439195B1 (ko) | 2013-04-18 | 2014-09-12 | 동아대학교 산학협력단 | 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정 |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| EP3055409B1 (en) * | 2013-10-11 | 2018-04-25 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| EP3099324B1 (en) | 2014-01-30 | 2020-04-01 | Coherus Biosciences, Inc. | Perfusion media |
| JP6609561B2 (ja) | 2014-02-04 | 2019-11-20 | バイオジェン・エムエイ・インコーポレイテッド | 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用 |
| JP6698681B2 (ja) | 2014-12-01 | 2020-05-27 | アムジエン・インコーポレーテツド | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
| KR102007930B1 (ko) | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
| CN105777897A (zh) * | 2015-03-20 | 2016-07-20 | 广东东阳光药业有限公司 | 一种cho细胞收获液的前处理方法 |
| CN114807010B (zh) * | 2015-04-01 | 2024-11-29 | 勃林格殷格翰国际公司 | 细胞培养基 |
| KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| CN110484487A (zh) * | 2019-08-21 | 2019-11-22 | 安徽欣乐生物技术有限公司 | 一种适用于cho细胞培养用无蛋白培养基及其培养方法 |
| WO2022140389A1 (en) | 2020-12-22 | 2022-06-30 | Amgen Inc. | Cell culture method |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| CN114480492B (zh) * | 2022-01-28 | 2023-04-21 | 景泽生物医药(合肥)股份有限公司 | 一种重组人抗体融合蛋白的制备方法 |
| CN119510778A (zh) * | 2024-12-31 | 2025-02-25 | 北京同立海源生物科技有限公司 | 一种高稳定性的pdgf-bb活性检测方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1990003430A1 (en) * | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US6291159B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| DE59010933D1 (de) | 1989-09-12 | 2003-05-08 | Hoffmann La Roche | TFN-bindende Proteine |
| AU638762B2 (en) * | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5156964A (en) * | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
| GB9118664D0 (en) * | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片 |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| US20020012991A1 (en) | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| ATE420114T1 (de) | 2001-04-30 | 2009-01-15 | Lilly Co Eli | Humanisierte antikörper die das beta-amyloid peptid erkennen& x9; |
| WO2002088307A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
| WO2002101019A2 (en) | 2001-06-13 | 2002-12-19 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL375045A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| TWI379693B (en) | 2002-05-02 | 2012-12-21 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
-
2005
- 2005-08-25 US US11/213,633 patent/US7300773B2/en not_active Expired - Lifetime
- 2005-08-25 TW TW094129077A patent/TWI364458B/zh not_active IP Right Cessation
- 2005-08-26 CN CN2005800369388A patent/CN101061231B/zh not_active Expired - Fee Related
- 2005-08-26 CN CN2012102771283A patent/CN102876761A/zh active Pending
- 2005-08-26 NZ NZ579208A patent/NZ579208A/en not_active IP Right Cessation
- 2005-08-26 PE PE2009001227A patent/PE20100448A1/es active IP Right Grant
- 2005-08-26 EP EP08005732A patent/EP1992697B1/en not_active Revoked
- 2005-08-26 PE PE2005000987A patent/PE20060815A1/es not_active Application Discontinuation
- 2005-08-26 UA UAA200703287A patent/UA89383C2/ru unknown
- 2005-08-26 RS RSP-2010/0190A patent/RS51255B/sr unknown
- 2005-08-26 HR HR20100011T patent/HRP20100011T1/hr unknown
- 2005-08-26 DK DK08005732.6T patent/DK1992697T3/da active
- 2005-08-26 AT AT08005732T patent/ATE461285T1/de active
- 2005-08-26 MY MYPI20054023A patent/MY137803A/en unknown
- 2005-08-26 AR ARP050103596A patent/AR050537A1/es not_active Application Discontinuation
- 2005-08-26 SV SV2005002211A patent/SV2006002211A/es unknown
- 2005-08-26 PL PL05791482T patent/PL1781802T3/pl unknown
- 2005-08-26 GT GT200500234A patent/GT200500234A/es unknown
- 2005-08-26 AU AU2005280036A patent/AU2005280036B2/en not_active Expired
- 2005-08-26 CA CA2578138A patent/CA2578138C/en not_active Expired - Lifetime
- 2005-08-26 ES ES05791482T patent/ES2335518T3/es not_active Expired - Lifetime
- 2005-08-26 ES ES08005732T patent/ES2341390T3/es not_active Expired - Lifetime
- 2005-08-26 DE DE602005020076T patent/DE602005020076D1/de not_active Expired - Lifetime
- 2005-08-26 EP EP05791482A patent/EP1781802B1/en not_active Revoked
- 2005-08-26 JP JP2007530167A patent/JP2008511330A/ja active Pending
- 2005-08-26 PT PT05791482T patent/PT1781802E/pt unknown
- 2005-08-26 SI SI200530984T patent/SI1992697T1/sl unknown
- 2005-08-26 SI SI200530874T patent/SI1781802T1/sl unknown
- 2005-08-26 PT PT08005732T patent/PT1992697E/pt unknown
- 2005-08-26 PL PL08005732T patent/PL1992697T3/pl unknown
- 2005-08-26 BR BRPI0514694A patent/BRPI0514694B8/pt active IP Right Grant
- 2005-08-26 KR KR1020077004810A patent/KR100988451B1/ko not_active Expired - Lifetime
- 2005-08-26 RU RU2007108717/10A patent/RU2458988C2/ru active
- 2005-08-26 DE DE602005017285T patent/DE602005017285D1/de not_active Expired - Lifetime
- 2005-08-26 GT GT200500233A patent/GT200500233A/es unknown
- 2005-08-26 DK DK05791482.2T patent/DK1781802T3/da active
- 2005-08-26 MX MX2007002381A patent/MX2007002381A/es active IP Right Grant
- 2005-08-26 AT AT05791482T patent/ATE446376T1/de active
- 2005-08-26 RS RSP-2009/0575A patent/RS51072B/sr unknown
- 2005-08-26 WO PCT/US2005/030439 patent/WO2006026447A2/en not_active Ceased
- 2005-08-26 HN HN2005000485A patent/HN2005000485A/es unknown
-
2007
- 2007-02-26 ZA ZA2007/01672A patent/ZA200701672B/en unknown
- 2007-02-27 EG EGNA2007000222 patent/EG26922A/xx active
- 2007-02-27 IL IL181588A patent/IL181588A/en unknown
- 2007-03-16 CR CR8998A patent/CR8998A/es unknown
- 2007-03-26 NO NO20071570A patent/NO344785B1/no not_active IP Right Cessation
- 2007-03-27 EC EC2007007354A patent/ECSP077354A/es unknown
-
2010
- 2010-01-08 CY CY20101100022T patent/CY1109721T1/el unknown
- 2010-05-14 HR HR20100271T patent/HRP20100271T1/hr unknown
- 2010-06-16 CY CY20101100556T patent/CY1110092T1/el unknown
-
2012
- 2012-02-17 JP JP2012033112A patent/JP5921910B2/ja not_active Expired - Lifetime
- 2012-11-01 CR CR20120560A patent/CR20120560A/es unknown
- 2012-11-09 AR ARP120104234A patent/AR088824A2/es not_active Application Discontinuation
-
2016
- 2016-01-28 JP JP2016014650A patent/JP2016056214A/ja active Pending
-
2017
- 2017-03-09 CL CL2017000577A patent/CL2017000577A1/es unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| R082 | Change of representative |
Ref document number: 1781802 Country of ref document: EP Representative=s name: REITSTOETTER, KINZEBACH & PARTNER (GBR), DE |
|
| R081 | Change of applicant/patentee |
Ref document number: 1781802 Country of ref document: EP Owner name: PFIZER IRELAND PHARMACEUTICALS, IE Free format text: FORMER OWNER: WYETH RESEARCH IRELAND LTD., NEWBRIDGE, IE Effective date: 20120824 |
|
| R082 | Change of representative |
Ref document number: 1781802 Country of ref document: EP Representative=s name: REITSTOETTER, KINZEBACH & PARTNER (GBR), DE Effective date: 20120824 |